Recent Company News

• 04:03 AM ET Feb 19, 2026
  

  Swedish Orphan Biovitrum downgraded to hold from buy at Danske Bank (timing uncertain) (SEK 415.80, -5.20)

• 10:40 AM ET Feb 18, 2026
  

  Transcript Intelligence: Swedish Orphan Biovitrum Capital Markets Day

• 03:57 AM ET Feb 10, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 03:53 AM ET Feb 18, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (139 total)

• 02:52 AM ET Feb 18, 2026
  

  Swedish Orphan Biovitrum releases presentation material in connection with its CMD (SEK 410.80, 0.00)

• 02:05 AM ET Feb 18, 2026
  

  Swedish Orphan Biovitrum AB aims to achieve adj EBITA margin in upper 30s percentage of revenue by 2030 -- CMD (SEK 410.80, 0.00)

• 01:02 AM ET Feb 16, 2026
  

  Sanofi's Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season (€77.62, 0.00)

• 04:31 AM ET Feb 10, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (133 total)

• 12:51 AM ET Feb 10, 2026
  

  Swedish Orphan Biovitrum upgraded to outperform from underperform at BNP Paribas Exane (SEK 395.80, 0.00)